U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT07504796) titled 'ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab' on March 26.
Brief Summary: The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incidence and severity of immune-related adverse events.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Metastatic Melanoma
Advanced Melanoma
Intervention:
DRUG: Nivolumab
480 mg Nivolumab every 4 weeks
DRUG: Relatlimab
160 m...